HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a price target of $17.
July 07, 2023 | 4:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ASLAN Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $17.
The reiteration of a 'Buy' rating and maintenance of a $17 price target by HC Wainwright & Co. indicates a positive outlook for ASLAN Pharma. This could potentially attract investors and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100